Abstract
Aims
Acute ischemic stroke (AIS) is the most common type of stroke.
Fingolimod is a sphingosine analog that acts on
sphingosine-1-phosphate
receptors(S1PR). Recently, the safety and efficacy of fingolimod in both
patients with intracerebral hemorrhage and patients with AIS have been
investigated in proof-of-concept trials. In this review, we performed a
meta-analysis to evaluate the efficacy and safety of fingolimod for AIS.